Immune-Onc: Immune-Onc doses first subject in trial of IO-108 for HCC
Immune-Onc has dosed the first subject in the Phase Ib/II trial of IO-108 plus Roche's atezolizumab and bevacizumab for HCC. The post Immune-Onc doses first subject in trial of IO-108 for HCC appeared first on Clinical Trials Arena.
Read full article »
Immune-Onc is a California-based biotechnology company that researches and develops immunotherapies for the treatment of cancer and solid tumors.
Read more